The PD-1/PD-L1 inhibitors market size is predicted to be valued at US$ 49.5 billion in 2023, rising to US$ 123.3 billion by 2033. Throughout the forecast period, the market is expected to grow at a substantial CAGR of 9.6%.
The usage of PD-1 and PD-L1 inhibitors, which are significant immune checkpoint inhibitors used as front-line treatments for a variety of cancers, has increased significantly due to the rising worldwide cancer burden. Pembrolizumab (KEYTRUDA) is in high demand around the world due to its proven efficacy in treating many FDA-approved indications. As a result, market participants are investing heavily in the development of these products, and this trend is expected to continue over the forecast period.
Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12644
The increase in research and development activities is expected to provide significant growth opportunities for key market players in the PD-1/PD-L1 inhibitors market.
To meet rising demand, market participants, for example, are increasing their investments in research and development.
- Researchers at Johns Hopkins Kimmel Cancer Center are pioneering the development of anti-PD-1 and anti-PD-L1 immunotherapies for patients with advanced melanomas. The goal of the therapy is not to directly kill cancer cells, but to block a pathway that protects tumor cells from immune system components that are capable and ready to fight cancer.
Key Takeaways
- The hospital pharmacies segment is anticipated to have a sizeable market share of 48.3% during the forecast period due to its significant customer base, rising healthcare costs, and rising cases of cancers such as lung and bladder cancer, melanoma, hodgkin lymphoma, and others.
- The United States is expected to generate a revenue of US$ 23.4 billion by 2033. The government is increasing funding and support for the development of new cancer drugs. Moreover, an increase in research and development for new and innovative pharmaceuticals in the market is driving regional growth.
- China is set to be a lucrative market and is likely to expand at an incredible rate of 14.0%. One of the primary reasons for the considerable growth of the PD-1 and PD-L1 inhibitors market is the sale of approved therapeutics and the increasing prevalence of blood-related tumors. The increasing patient assistance programs offered by vendors are propelling the market in this region forward.
- Pembrolizumab is anticipated to increase at a rate of 8.7% during the projected period and reached a substantial market share of 49.5% in 2022. Due to pembrolizumab’s demonstrated effectiveness in treating FDA-approved indications, including head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), melanoma, and others, its use has increased
- Tamil Nadu in India is developing a treatment policy to identify 66.0% of cancer patients in the first and second stages by 2030, allowing for proper treatment. As a result, such a policy is expected to fuel demand for PD-1 inhibitor drugs, propelling the growth of the segment over the forecast period.
Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-12644
Manufacturers are Constantly Evolving Business Models
Companies in the PD-1/PD-L1 inhibitors market are moderately competitive by nature, with several key players present. These players are part of several strategic alliances. The agreement and system automation speed up the manufacturer’s strategy to capitalize on market share and capture a sizable market share.
Key Players:
- Akeso Inc.
- Alphamab Oncology
- Amgen Inc.
- AstraZeneca Plc
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly and Co.
- Others
Latest Developments
- Novartis International AG acquired The Medicines Company in January 2020. This acquisition aided Novartis in using a vaccine-like approach to treat the world’s leading cause of mortality and disability.
- Merck announced the FDA approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, in October 2021. Patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] 1) as determined by an FDA-approved test are given the therapy.
Get Customization on This Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-12644
PD-1/PD-L1 Inhibitors Market Segment by Category
By Product:
- Nivolumab
- Pembrolizumab
- Atezolizumab
- Avelumab
- Durvalumab
By Indication:
- Melanoma
- Non-Small Cell Lung Cancer (NSCLC)
- Renal Cell Carcinoma (RCC)
- Head and Neck Squamous Cell Cancer (HNSCC)
- Bladder Cancer
- Merkel Cell Carcinoma (MCC)
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
